|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tepper RI, Pattengale PK and Leder P:
Murine interleukin-4 displays potent anti-tumor activity in
vivo. Cell. 57:503–512. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iinuma H, Okinaga K, Fukushima R, et al:
Superior protective and therapeutic effects of IL-12 and IL-18
gene-transduced dendritic neuroblastoma fusion cells on liver
metastasis of murine neuroblastoma. J Immunol. 176:3461–3469. 2006.
View Article : Google Scholar
|
|
4
|
Siddiqui F, Li CY, Larue SM, et al: A
phase I trial of hyperthermia-induced interleukin-12 gene therapy
in spontaneously arising feline soft tissue sarcomas. Mol Cancer
Ther. 6:380–389. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coca S, Enrech S, Moreno Garcia V, et al:
Evaluation of the antitumor activity of interleukin-12 in an
experimental murine model of colorectal cancer induced by 1,2
dimethyl-hydrazine (DMH). Rev Esp Enferm Dig. 97:619–628. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hill HC, Conway TF Jr, Sabel MS, et al:
Cancer immunotherapy with interleukin 12 and granulocyte-macrophage
colony-stimulating factor-encapsulated microspheres: coinduction of
innate and adaptive antitumor immunity and cure of disseminated
disease. Cancer Res. 62:7254–7263. 2002.
|
|
7
|
Wolff JA, Malone RW, Williams P, et al:
Direct gene transfer into mouse muscle in vivo. Science.
247:1465–1468. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang KS, Cho WK, Yoo J, Yun HJ, Kim S and
Im DS: Adenovirus-mediated interleukin-12 gene transfer combined
with cytosine deaminase followed by 5-fluorocytosine treatment
exerts potent antitumor activity in Renca tumor-bearing mice. BMC
Cancer. 5:512005. View Article : Google Scholar
|
|
9
|
Shi F, Rakhmilevich AL, Heise CP, et al:
Intratumoral injection of interleukin-12 plasmid DNA, either naked
or in complex with cationic lipid, results in similar tumor
regression in a murine model. Mol Cancer Ther. 1:949–957.
2002.PubMed/NCBI
|
|
10
|
Sangro B, Mazzolini G, Ruiz J, et al:
Phase I trial of intratumoral injection of an adenovirus encoding
interleukin-12 for advanced digestive tumors. J Clin Oncol.
22:1389–1397. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keke F, Hongyang Z, Hui Q, Jixiao L and
Jian C: A combination of flk1-based DNA vaccine and an
immunomodulatory gene (IL-12) in the treatment of murine cancer.
Cancer Biother Radiopharm. 19:649–657. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang WQ, Wang LN and Liu ZJ: Functional
evaluation of recombinant human IL-12 ex vivo with cytokine follow
cytometry (CFC). Chin J Micobiol Immunol. 26:383–384. 2006.
|
|
13
|
Wagner HJ, Bollard CM, Vigouroux S, et al:
A strategy for treatment of Epstein-Barr virus-positive Hodgkin’s
disease by targeting interleukin 12 to the tumor environment using
tumor antigen-specific T cells. Cancer Gene Ther. 11:81–91.
2004.
|
|
14
|
Wang LL and Wu JM: Clinical Laboratory
Immunology. The People’s Medical Publishing House; Beijing: pp.
369–370. 2008
|
|
15
|
Duan X, Jia SF, Koshkina N and Kleinerman
ES: Intranasal interleukin-12 gene therapy enhanced the activity of
ifosfamide against osteosarcoma lung metastases. Cancer.
106:1382–1388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jaime-Ramirez AC, Mundy-Bosse BL,
Kondadasula S, et al: IL-12 enhances the antitumor actions of
trastuzumab via NK cell IFN-gamma production. J Immunol.
186:3401–3409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tatsumi T, Huang J, Gooding WE, et al:
Intratumoral delivery of dendritic cells engineered to secrete both
interleukin (IL)-12 and IL-18 effectively treats local and distant
disease in association with broadly reactive Tc1-type immunity.
Cancer Res. 63:6378–6386. 2003.
|
|
18
|
Segal JG, Lee NC, Tsung YL, Norton JA and
Tsung K: The role of IFN-gamma in rejection of established tumors
by IL-12 : source of production and target. Cancer Res.
62:4696–4703. 2002.PubMed/NCBI
|
|
19
|
Lode HN, Dreier T, Xiang R, Varki NM, Kang
AS and Reisfeld RA: Gene therapy with a single chain interleukin 12
fusion protein induces T cell-dependent protective immunity in a
syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA.
95:2475–2480. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao Z, Baguley BC and Ching LM:
Interferon-inducible protein 10 induction and inhibition of
angiogenesis in vivo by the antitumor agent
5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res.
61:1517–1521. 2001.PubMed/NCBI
|
|
21
|
Yang SHJ: Pharmacology. The People’s
Medical Publishing House; Beijing: pp. 5012005
|
|
22
|
Wolff JA, Dowty ME, Jiao S, et al:
Expression of naked plasmids by cultured myotubes and entry of
plasmids into T tubules and caveolae of mammalian skeletal muscle.
J Cell Sci. 103:1249–1259. 1992.PubMed/NCBI
|
|
23
|
Jiao H, Soejima Y, Ohe Y, Miura K, Tamura
T and Saijo N: Differential macrophage-mediated cytotoxicity to
P388 leukemia cells and its drug-resistant cells examined by a new
MTT assay. Leuk Res. 16:1175–1180. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Imboden M, Shi F, Pugh TD, et al: Safety
of interleukin-12 gene therapy against cancer: a murine
biodistribution and toxicity study. Hum Gene Ther. 14:1037–1048.
2003. View Article : Google Scholar : PubMed/NCBI
|
